You just read:

Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Jul 28, 2015, 08:00 ET